Lakewood-Amedex Biotherapeutics (LABT) investor relations material

Executive summary

• Annual Meeting scheduled for September 22, 2026, to be held virtually, with record date set as July 30, 2026.

• Key proposals include director elections, amendments to articles of incorporation, reverse stock split authorization, equity plan increase, and auditor ratification.

• Shareholders can vote online, by phone, mail, or during the virtual meeting.

Voting matters and shareholder proposals

• Election of four directors for one-year terms: Kelvin Cooper, Doug Manion, Leonard J. DeRoma, and Joseph Tucker.

• Proposal to increase authorized common stock from 12,500,000 to 100,000,000 shares.

• Authorization for the Board to effect one or more reverse stock splits up to a 1:20 ratio, at its discretion, by September 22, 2027.

• Amendment to the 2020 Equity Incentive Plan to increase shares issuable to 400,000.

• Ratification of CBIZ CPAs P.C. as independent auditor for fiscal year ending December 31, 2026.

Board of directors and corporate governance

• Board consists of four members, with three deemed independent under Nasdaq standards.

• Committees established: Finance, Audit & Risk; Compensation; Corporate Governance & Nominating, all composed of independent directors.

• Board and committees oversee risk, compensation, governance, and nominations.

• Code of Business Conduct applies to all directors, officers, and employees.